Skip to main content
DTIL
NASDAQ Life Sciences

Precision BioSciences Reports First-Ever Clinical Evidence of cccDNA Elimination in Hepatitis B Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$8
Mkt Cap
$195.581M
52W Low
$3.53
52W High
$8.82
52W Position info
127% above low
Off High info
9.3% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

DTIL has more than doubled off its 52-week low of $3.53.

Summary

Precision BioSciences reported highly positive clinical data from its ELIMINATE-B trial, showing the first-ever direct elimination of cccDNA in chronic hepatitis B patients, a key step towards a cure.


Key Events · Product Development and Regulatory · DTIL

  • First Clinical Evidence of cccDNA Elimination

    New biopsy data from the Phase 1 ELIMINATE-B trial demonstrated that PBGENE-HBV directly eliminated cccDNA, leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. This marks the first clinical evidence of a therapeutic agent achieving cccDNA elimination and inactivation in liver biopsies for chronic hepatitis B.

  • 100% pgRNA Loss in Patients

    New clinical data showed PBGENE-HBV achieved pgRNA loss in 100% of patients (n=6) with detectable pgRNA at baseline. Complete loss of detectable blood pgRNA directly corresponded to undetectable pgRNA in post-treatment liver biopsy, establishing pgRNA as a key biomarker for cccDNA elimination.

  • Manageable Safety Profile

    The trial demonstrated a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts. While transient Grade 3 ALT/AST abnormalities and Grade 3 hypotension were observed, mitigation protocols have been implemented, and no further severe events have occurred since.

  • Substantial HBsAg Declines

    100% of patients (n=15) experienced substantial HBsAg declines, consistent with PBGENE-HBV's mechanism of cccDNA elimination. The duration of response is ongoing, with some patients showing durable HBsAg decline for over a year.


Analysis · DTIL · Life Sciences

Precision BioSciences announced groundbreaking clinical data from its ELIMINATE-B trial for chronic hepatitis B, demonstrating the first-ever clinical evidence of cccDNA elimination in liver biopsies. This is a critical step towards a functional cure for hepatitis B, a disease with significant unmet medical need. The data shows a 10-fold reduction in cccDNA-derived transcripts and 100% pgRNA loss in treated patients, alongside a manageable safety profile, indicating strong therapeutic potential.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DTIL was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.6M. The 52-week trading range was $3.53 to $8.82. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $9.01 info
Change: +$1.28 (+17%) info
Market Cap: $255.612M info
DTIL
Nov 05, 2026, 7:07 AM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $9.01 info
Change: +$0.510 (+6%) info
Market Cap: $255.612M info
DTIL
Nov 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $9.01 info
Change: +$0.620 (+7%) info
Market Cap: $255.612M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $9.01 info
Change: +$0.440 (+5%) info
Market Cap: $255.612M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $9.01 info
Change: +$0.620 (+7%) info
Market Cap: $255.612M info